Aethlon Medical (AEMD) EBIT (2010 - 2026)

Aethlon Medical's EBIT history runs 17 years deep, the most recent figure standing at -$1.9 million for Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 3.73% year-over-year to -$1.9 million; the trailing twelve-month figure through Mar 2026 stood at -$7.3 million (up 21.92% YoY), and the FY2026 full-year result was -$7.3 million, up 21.92% from the prior year.
• EBIT was -$1.9 million for Q1 2026 at Aethlon Medical, up from -$2.1 million in the prior quarter.
• Over the last five years, EBIT for AEMD reached as high as -$1.5 million in Q3 2025 and fell as low as -$3.8 million in Q1 2022.
• Median EBIT over the past 5 years was -$2.6 million (2024), compared with a mean of -$2.6 million.
• Across the five-year window, EBIT plunged 82.46% in 2022 and jumped 49.13% in 2024, its largest moves.
• Over 5 years, EBIT stood at -$2.8 million in 2022, then decreased by 25.17% to -$3.6 million in 2023, then jumped by 49.13% to -$1.8 million in 2024, then dropped by 13.63% to -$2.1 million in 2025, then gained by 6.44% to -$1.9 million in 2026.
• Business Quant data shows AEMD's EBIT at -$1.9 million in Q1 2026, -$2.1 million in Q4 2025, and -$1.5 million in Q3 2025.